January 20, 2012—The Office of Pharmacy Affairs (OPA) has begun its first-ever audits of 340B covered entities to determine if they are eligible to receive drug discounts, if they have sold or diverted discounted drugs to ineligible patients, and if they are able to prevent and detect instances of drug diversion and duplicate discounts.
Some hospitals have received letters from OPA Director Krista Pedley informing them that they have been selected for an audit of their compliance with 340B program requirements, summarizing what the review will cover, and requesting “specific times for an entrance conference” this month with key hospital management and personnel involved in the 340B program “to collect relevant documents.”
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)